GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Cyclically Adjusted Price-to-FCF

Traws Pharma (FRA:0T2) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Traws Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Cyclically Adjusted Price-to-FCF Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Traws Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted Price-to-FCF falls into.



Traws Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Traws Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Traws Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.193/129.4194*129.4194
=-0.193

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -11,739.000 99.695 -15,239.099
201406 -10,429.000 100.560 -13,422.053
201409 -10,238.000 100.428 -13,193.516
201412 -11,578.000 99.070 -15,124.885
201503 -9,105.000 99.621 -11,828.454
201506 -7,549.000 100.684 -9,703.508
201509 -7,013.000 100.392 -9,040.788
201512 -4,627.000 99.792 -6,000.693
201603 -4,112.000 100.470 -5,296.810
201606 -3,573.000 101.688 -4,547.391
201609 -1,272.500 101.861 -1,616.774
201612 -2,068.000 101.863 -2,627.452
201703 -2,831.000 102.862 -3,561.914
201706 -1,689.000 103.349 -2,115.058
201709 -2,069.000 104.136 -2,571.347
201712 -1,316.333 104.011 -1,637.893
201803 -1,117.000 105.290 -1,372.990
201806 -219.889 106.317 -267.671
201809 -245.240 106.507 -297.998
201812 -190.200 105.998 -232.227
201903 -224.692 107.251 -271.136
201906 -167.077 108.070 -200.084
201909 -133.222 108.329 -159.158
201912 -9.765 108.420 -11.656
202003 -8.203 108.902 -9.749
202006 -0.423 108.767 -0.503
202009 -0.406 109.815 -0.478
202012 -0.364 109.897 -0.429
202103 -0.382 111.754 -0.442
202106 -0.227 114.631 -0.256
202109 -0.227 115.734 -0.254
202112 -0.180 117.630 -0.198
202203 -0.187 121.301 -0.200
202206 -0.191 125.017 -0.198
202209 -0.188 125.227 -0.194
202212 -0.175 125.222 -0.181
202303 -0.202 127.348 -0.205
202306 -0.198 128.729 -0.199
202309 -0.199 129.860 -0.198
202312 -0.193 129.419 -0.193

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Traws Pharma  (FRA:0T2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Traws Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Industry
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines